Table 3.

Stem cells targeted therapies in pSS patients.

MSCs	Cell Number, Origin	Administration	Effect	Refs
UMSCs	1 × 106 /Kg one dose	iv	Increase saliva flow, reduction in anti-SSA/Ro and anti-SSB/La antibodies	[257]
UMSCs	Human N/A	Coculture	Differentiation and proliferation of Tfh cells decreased	[256]
UMSCs microencapsulated	Human N/A	Coculture	Decrease in proliferation of T cells, and numbers of Th1, Th17; Treg increased	[258]
UMSCs	Human 1 × 106 /Kg	iv	Reduced IL-12, decrease inTh17 and Tfh cells; Treg increased	[259]

This table displays SS therapies targeting mesenchymal stem cell (MSC). The table shows the origin of the MSCs, injected cell number, route of administration, effect of treatment, and references. Abbreviations: UMSCs—Umbilical cord-derived mesenchymal stem cell, iv—intravenous, SSA—Sjögren’s syndrome A antibodies, SSB—Sjögren’s syndrome B antibodies, Tfh—T follicular helper, Th1—T helper type 1, Th17—T helper 17, Treg—T regulatory cells, and IL-12—Interleukin-12.